Concepedia

Yasmin Hashambhoy-Ramsay

YH

Statistics

Publications

3

Citations

181

H-Index

3

Active since

2016

Affiliations

Akebia Therapeutics (United States)(Current)

Yasmin Hashambhoy-Ramsay is an author at Akebia Therapeutics (United States) specializing in cancer immunotherapy, medicine, and oncology.

ORCID

Publications per year

2016–2023

3

Publications

3

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Timothy A. Yap, Justin F. Gainor, Margaret K. Callahan et al. · Clinical Cancer Research · 2022 · 97 citations · Full text

, , +17

Flt-1 (VEGFR-1) coordinates discrete stages of blood vessel formation

John C. Chappell, Julia G. Cluceru, Jessica E. Nesmith et al. · Cardiovascular Research · 2016 · 50 citations · Full text

, , +16

Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors

Ben Umiker, Yasmin Hashambhoy-Ramsay, Jeff Smith et al. · Molecular Cancer Therapeutics · 2023 · 34 citations

, , +17

1–3 of 3